Clinical Research Directory
Browse clinical research sites, groups, and studies.
IBS Personalized Diet vs. Low FODMAP Diet Randomized Control Trial
Sponsor: Weizmann Institute of Science
Summary
Irritable bowel syndrome (IBS) is considered the most common gastrointestinal disorder in humans, with an estimated global prevalence of 11%-20% of all humans. Alterations in the gut microbiome are at the center of IBS, and microbiome-induced volatile metabolites in response to dietary exposures is believed to drive a downstream impact on susceptible hosts, thereby driving the disease. However, the characteristics and functions of these metabolites remain unknown to date. This placebo-controlled interventional study examines person-specific small molecules and bacteria driving IBS and their downstream effects on the human gut epithelium.
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2026-05-11
Completion Date
2029-11
Last Updated
2026-10-15
Healthy Volunteers
No
Conditions
Interventions
Standard Low FODMAP dietary regimen
Standard low FODMAP dietary regimen randomized re-introduction phase
personalized low FODMAP dietary regimen
Low FODMAP dietary regimen with personalized re-introduction phase
Locations (1)
Weizmann institute of science
Rehovot, Israel